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1. INTRODUCTION 
 
The discovery of Helicobacter pylori infection in 1983 and its association with peptic 
ulcer disease was a major achievement in medicine, which brought by a major change in 
the understanding of peptic ulcer disease, a common chronic disease, which now could be 
explained by a bacterial infection [1;2]. From a public health view, the last three decades 
have been most interesting concerning H. pylori and related disorders. In Western 
countries the prevalence and incidence of peptic ulcer disease have decreased [3], parallel 
to a decrease of the prevalence of H. pylori (Paper III) [4-7]. As a consequence of this, 
the role of H. pylori infection in peptic ulcer disease is now less prominent than earlier  
[8], and the enthusiasm that followed the idea that we had a simple cure for peptic ulcer 
disease has levelled out. However, the remaining cases have a broader spectre of causes, 
of which the use of ulcerogenic medications such as acetylsalicylic acid (ASA) [9] and 
non-steroidal anti-inflammatory drugs (NSAID) [10], as well as smoking deserves special 
attention [11;12].  
Dyspepsia is world-wide a highly prevalent health issue [13;14], involving substantial 
and increasing costs [15;16]. Previously, when peptic ulcer disease was more common, a 
larger proportion of dyspepsia was linked to peptic ulcer disease, and thus to H. pylori. 
So far, the research of the relationship between dyspepsia and H. pylori reflects a period 
with a higher prevalence of H. pylori than today, in most developed countries. The 2007 
Maastricht III consensus report [17], that advocates an approach of testing for and 
treating H. pylori, in cases of dyspepsia in the absence of alarm signals, is thus based on 
premises that are changing. The prevalence of H. pylori thus has implications for the 
effectiveness of management strategies for dyspepsia [18]. 
When discussing strategies of management of dyspepsia and H. pylori, upper endoscopy 
is often considered an option [19-21]. Endoscopy is a costly, time consuming procedure 
and not free of risk, even though complications are rare [22;23].The benefit of the method 
may not justify its common use in cases of mild dyspepsia, and the diagnostic uncertainty 
attached to upper endoscopy deserves more attention [24] [25]. 
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In 1987 Bjørn Bernersen and co-workers initiated the Sørreisa Gastrointestinal Disorder 
Study, a population-based study on non-ulcer dyspepsia and its possible risk factors. 
Sørreisa was chosen because Per Stakkevold, a general practitioner in Sørreisa for many 
years, worked at the Department of Gastroenterology in Tromsø at the time of planning 
the study. Dr. Stakkevold joined the group, and thus made the choice of Sørreisa evident. 
The cross-sectional study in Sørreisa in 1987 forms a good basis both for a follow-up 
study, and a study of the changing epidemiology of H. pylori and dyspepsia. 
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2. AIMS OF THE THESIS 
 
After two decades of awareness of H. pylori as a potential pathogen and the subsequent 
management of H. pylori related disorders, it is time to reflect upon its role in the general 
population.  What is the role of dyspepsia in a general population in Norway today, and is 
there an association between H. pylori and dyspepsia? The specific aims of this thesis 
are: 
 
1. To investigate if H. pylori antigen detection in stool is a valid and accurate 
diagnostic test 
2. To examine the extent of inter- and intra-observer variation in assessment of images 
from upper endoscopy, in order to assess their usefulness in the reports of upper 
endoscopy.  
3. To study the changes in prevalence of dyspepsia and H. pylori infection, as well as 
their mutual relationship in a general population.  
4. To investigate the natural course of H. pylori infection with regard to gastritis, 
peptic ulcer and oesophagitis.  
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3. MATERIAL AND METHODS 
 
3.1. Data sources 
3.1.1. Validation of the H. pylori stool antigen test 
From October 2002 to October 2003 patients with upper abdominal complaints, referred 
to the outpatient Clinic of Gastroenterology, University Hospital of North Norway, were 
enrolled in the study of the H. pylori stool antigen test. The test chosen was the Amplified 
IDEIA Hp StAR (DacoCytomation Norden, Denmark), which uses an enzyme-linked 
immunosorbent assay amplifying technique. The stool specimens were sent by regular 
mail and processed according to the manufacturer’s instructions. A total of 131 subjects 
were enrolled, which was about half of those considered for the study. As 9 dropped out, 
the primary validation was thus based on 122 persons. In the subsequent study of whether 
test performance was influenced by treatment with proton pump inhibitor, 39 persons 
contributed (43 were enrolled, 4 were excluded due to misunderstanding of instructions). 
The final part of the test validation study, in which 32 persons contributed, concerned 
patients after eradication treatment (Paper I). Reasons for not enrolling intended subjects 
in the study varied from the presence of exclusion criteria, refusal, to logistic reasons, the 
latter being the most common. For ethical reasons, we could not ask the patients for 
reasons for not participating.  
 
3.1.2. Data acquisition in  Sørreisa  
Both the first and the second part of the Sørreisa Gastrointestinal Disorder Study were 
initiated and conducted by the University of Tromsø. The first part took place in 1987, in 
which Bjørn Bernersen and co-workers invited all adults aged 20 or above to answer a 
questionnaire on gastrointestinal disorders. Responders with dyspepsia, and an age and 
gender matched control group were invited to upper endoscopy. 
The second part of the Sørreisa Gastrointestinal Disorder Study took place in 2004, in 
which we invited all adults aged 18 to 85 to answer a questionnaire and send stool 
samples for H. pylori detection. In the questionnaire we asked permission to invite 
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responders to partake in upper endoscopy. Those who accepted were all invited, and the 
endoscopy study in 2004 had thus a cross-sectional design in contrast to the case-control 
design in 1987. We also invited the cohort who underwent endoscopy in 1987, to have a 
new examination again in 2004, regardless of whether or not they answered the 
questionnaire. Follow-up of the cohort of participants from 1987 was for formal reasons 
restricted to those still living in Sørreisa.    
The combination of two cross-sectional studies, one in 1987 and one in 2004, in addition 
to a cohort study including the participants of both studies, challenged us 
methodologically. In paper III, we chose to supplement our cross-sectional analyses of 
the relationship between dyspepsia and H. pylori with a longitudinal analysis. In the 
longitudinal analysis all subject participating either in 1987 or in 2004 were included, and 
in addition it was taken into consideration if they provided information at both times.  
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Figure 1. Sørreisa Gastrointestinal Disorder Study 1987 and 2004 
 
The arrows present the flow of participants of the study in 1987 into the study in 2004, 
and thus the cohort we followed. Rectangular boxes indicate participants. Oval boxes 
indicate non-responders or those who were lost to follow-up. The boxes presenting 
participants in 1987 are exclusive, whereas the boxes presenting participants in 2004 are 
not exclusive. (See 9. Errata p. 45) 
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Figure 2. Distribution of the 1193 Participants in the Sørreisa Gastrointestinal Disorder 






In 1987 there were no generally accepted international criteria for the definition of 
dyspepsia, thus the study group had to make questions and definitions themselves. The 
following two questions were used to define subjects with dyspepsia; “Have you ever had 
abdominal pain located in the upper abdomen for at least 2 weeks?” and “Have you ever 
had heartburn or acid regurgitation almost daily for at least one week?” A positive answer 
to either or both questions defined dyspepsia. In 2004 we chose to repeat these questions 
in order to secure the internal validity of the study, this time with a slightly different 
phrasing: “Have you since 1987 had abdominal pain located in the upper abdomen for at 
least 2 weeks?” and “Have you since 1987 had heartburn or acid regurgitation almost 
daily for at least one week?” Again, a positive answer to one or both questions defined 
dyspepsia. In addition we added the Gastrointestinal Symptom Rating Scale (GSRS) [26], 
one of several validated questionnaires on gastrointestinal disorders, in order to secure 
the external validity. The original GSRS scale of scores (0 to 3) were expanded to include 
half-points (0 to 7), as used by others [27;28]. 
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A first reminder was sent to non-responders asking for both questionnaire and stool 
samples, and a second reminder asking just for the questionnaire.  The complete 
questionnaires are shown in Appendices 2 and 3. 
 
3.1.2.2. Endoscopy in Sørreisa 
The endoscopy examinations of the population based study in Sørreisa in 2004 were done 
in a provisional endoscopy unit at the local Community Health Centre. Four Olympus 
GIF-160 video endoscopes, complete with light source and processor, as well as a 
washing machine were leased from Olympus Norway. The computer software Endobase 
III (Microsoft Corporation, Redmond, Wash., USA) was used for keeping records and 
capturing and storing of images from the examinations. The records followed a simplified 
version of the Minimal Standard Terminology of Digestive Endoscopy (MST) [29] 
recommended by the World Organization of Gastrointestinal Endoscopy (OMED). The 
MST defines peptic ulcer as a mucosal defect with a diameter of more than 5 mm, which 
appears to deeply involve the wall of the stomach or duodenum.  Peptic ulcer was defined 
in the same way in 1987 [30]. The protocol included capturing four routine images; one 
each from the distal oesophagus, the gastric fundus, the pyloric antrum, and the duodenal 
bulb. All subjects were offered local anaesthesia of the pharynx with lidocaine spray of 
the pharynx. Biopsies were sampled for histological examination, one each from the 
pyloric antrum and one from the greater curvature. Two further biopsies were stored in a 
special buffer solution (“RNA Later”) for subsequent DNA/RNA analysis (this material 
has not yet been used). 
We encountered only minor problems in the endoscopy unit in Sørreisa. In 16 cases there 
were technical problems with either capturing pictures or writing the report. In 8 cases 
examination was aborted due to lack of compliance. Only in one examination did we 
encounter a minor complication, which was prolonged bleeding after biopsy. In addition 
to the examinations related to the study protocol, additional diagnosis or follow up was 
done in 62 subjects, e.g. histological examination of polyps, examination of celiac disease 
on request, histological examination of ulcers. Of these, the 20 subjects who had findings 
requiring medical treatment, such as ulcers or severe oesophagitis, were referred to the 
outpatient clinic at the University Hospital of North Norway.  
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3.1.2.3. Laboratory analysis 
The stool samples were sent by mail to the Gastroenterology laboratory at the University 
Hospital of North Norway for analysis with the Amplified IDEIA Hp StAR® according to 
the manufacturer’s instructions, by the same personnel who did the analyses in the test 
validation study. 
Blood samples were collected in connection to the endoscopy examinations. Serum was 
stored at -20o C (this material has not yet been used). 
 
3.1.3. Statistics Norway and Cancer Registry 
Additional information regarding the participants of the study in 1987 was obtained from 
health registers. Specific causes of death were obtained from the Cause of Death Registry 
at Statistics Norway. Cancer diagnoses were obtained from the Cancer Registry of 
Norway.  Only 9 of the 1957 participants had developed gastric cancer during follow up 
(5 men, 4 women; 4 with dyspepsia, 5 without dyspepsia; Birth year 1913-1933). Gastric 
cancer was the primary cause of death in five of these subjects. One of the subjects who 
developed gastric cancer had undergone gastroscopy in 1987, where she was found H. 
pylori negative. Four participants died from peptic ulcer disease during follow up, and 
only in two cases was peptic ulcer disease the primary cause of death. None of these four 
subjects had been tested for H. pylori in 1987. The limited number of cancer and causes 
of death due to upper GI diseases is the reason why these endpoints are not addressed 
further in the papers, or the thesis. 
 
3.1.4. Internet survey on observer variation 
Ten images from the oesophagus and 10 from the pyloric antrum were used to set up an 
internet interface with a questionnaire for assessment of the images.  The images were 
obtained at the endoscopy examinations in Sørreisa in 2004, and were selected to ensure 
both normal and pathological findings as well as good technical quality. A simplified 
version of the Minimal Standard Terminology for Digestive Endoscopy [31] was used in 
the questionnaire (Appendix 1). Twenty physicians practising endoscopy in Northern 
Norway were invited to partake in the study, of which 13 responded. Responders could 
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answer anonymously, but were also given the opportunity to identify themselves in order 
to be contacted again. The assessment of the images was entered directly into a database 
at the Department of Community Medicine. After 5 months the 11 physicians who had 
initially identified themselves were invited to assess the same images again. This time 10 
responded. Analysis of inter-observer variation was done after the first assessments, and 
analysis of intra-observer variation was done after the second assessment. All responses 
were made anonymous before analysis. 
 
3.2. Statistical analyses  
Estimates of effect and differences are reported with 95% confidence intervals. From 
univariable logistic regression models, p-values less than 0.25 were used for building 
multivariable logistic regression models. P-values of 0.05 or less in final models were 
considered significant. Analyses were done using SPSS statistical software (SPSS Inc., 
Chicago, Ill., USA), Microsoft® Office Excel 2003 (Microsoft, Redmond, WA, USA) 
and SAS software package version 9.1 (SAS Institute Inc, Cary, USA). Agreement 
between observations was measured with kappa statistics [32], and values were 
categorized as described by Altman [33] as poor (κ ≤ 0.2), fair (0.21 ≤ κ ≤ 0.4), moderate 
(0.41 ≤ κ ≤ 0.6), good (0.61 ≤ κ ≤ 0.8), or excellent (κ ≥ 0.8). Measures of sensitivity, 
specificity and likelihood ratio were used for presenting test performance. 
 
3.3. Ethical and legal aspects 
The Regional Committee for Medical Research Ethics approved the Sørreisa study both 
in 1987 and in 2004, as well as the H. pylori test validation study. Participants gave 
written informed consent. License to register participants was granted by the Norwegian 
Data Inspectorate, in addition to a license to link the person registry of the 1987 study to 
the Cause of Death Registry at Statistics Norway and the Cancer Registry of Norway. 
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4. MAIN RESULTS 
4.1. Paper I. Accuracy of a monoclonal antibody-based stool antigen 
test in the diagnosis of Helicobacter pylori Infection 
A total of 131 patients referred for upper abdominal pain were enrolled in the study, of 
which 9 failed to send a stool sample. The test in question, the Amplified IDEIA Hp 
StAR® was found to have a sensitivity of 98% and a specificity of 94%, and a likelihood 
ratio for positive test results of 16.7, and likelihood ratio for negative test results of 0.02. 
The specificity of 94% reflects a false negative rate of 6%. In the subsequent analyses of 
the influence of proton pump inhibitor (PPI) on test performance, none of 43 H. pylori 
infected had a negative test result after one week of treatment. After two weeks, 2 of 39 
(5%) had a negative test result, which is within the expected number of false negatives. 
Up to two weeks use of PPI did thus not influence on test performance. The last part of 
the study, concerning control after H. pylori eradication, showed that all study subjects 
had successfully been treated and that there were no positive results of the test.  In 
conclusion, the Amplified IDEIA Hp StAR was considered an accurate, convenient 
diagnostic instrument in an outpatient setting.  
 
4.2. Paper II.  Impact of observer variability on the usefulness of 
endoscopic images for the documentation of upper gastrointestinal 
endoscopy  
Ten images from the distal oesophagus and 10 images from the pyloric antrum were 
presented on an internet interface together with a multiple choice questionnaire. Inter-
observer agreement varied between poor (κ ≤ 0.2), and moderate (0.41 ≤ κ ≤ 0.6). Intra-
observer agreement varied between moderate (0.41 ≤ κ ≤ 0.6), and good (0.61 ≤ κ ≤ 0.8). 
Higher experience did not lead to higher agreement. Concise findings, such as ulcers, 
yielded higher agreement than less definable findings. The variation in assessment of 
images from endoscopy was large, and the incorporation of standard images in the 
endoscopy record could be useful to reveal and improve this. 
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4.3. Paper III.  Changes in the prevalence of dyspepsia and 
Helicobacter pylori infection after 17 years: The Sørreisa 
gastrointestinal disorder study 
We compared changes in the prevalence of dyspepsia and H. pylori in two cross-sectional 
studies, in 1987 and in 2004. Dyspepsia was persistently prevalent and affected 31.9% of 
men and 31.7% of women in 2004, compared with 30.7% and 26.3% respectively in 
1987. In both subjects with and without dyspepsia, the prevalence of H. pylori infection 
had decreased significantly during the 17 years of observation, though the decrease of 6% 
in men without dyspepsia was not statistically significant. The overall age-adjusted 
prevalence of H. pylori infection was 25% in 2004. A longitudinal logistic regression 
model revealed that among men H. pylori was positively associated with dyspepsia in 
1987, whereas in 2004 there was a negative association between H. pylori and dyspepsia. 
Among women there was no association between H. pylori and dyspepsia at any time. In 
conclusion, a decreasing prevalence of H. pylori infection, a persistently high prevalence 
of dyspepsia, and a divergent distribution between H. pylori and dyspepsia in the two 
genders all together question a causal relationship. 
 
4.4. Paper IV. The natural course of Helicobacter pylori in gastritis, 
peptic ulcer disease and reflux oesophagitis in a population-based 
prospective cohort: The Sørreisa Gastrointestinal Disorder Study   
In this prospective cohort study H. pylori was a strong risk factor for inflammation of the 
gastric mucosa, a moderate risk factor for atrophy of the antrum, but not a risk factor for 
atrophy of the gastric body or intestinal metaplasia. The elimination of H. pylori infection 
led to regression of both inflammation and atrophy, but did not cause regression of 
intestinal metaplasia once it had developed. H. pylori was a moderate risk factor for 
peptic ulcer in men only. In women the use of acetylsalicylic acid was a more important 
risk factor for peptic ulcer. In analyses including both genders, smoking was an 
independent risk factor for peptic ulcer. In men H. pylori was protective against 
oesophagitis. Men ran a higher risk of both peptic ulcer and oesophagitis than women.   
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5. GENERAL DISCUSSION 
 
5.1. Insurance of participants  
Whereas the research ethics and legal aspects of registering participants in the H. pylori 
test validation study was uncomplicated, we had major challenges with the endoscopy 
study in Sørreisa. The Regional Committee for Medical Research Ethics raised questions 
about the health insurance of the study participants. A month before we presented the 
study for the committee, it had become clear that the issue of insurance of healthy 
research subjects was not clear in "The Norwegian System of Compensation to Patients" 
(NPE). Invasive procedures such as endoscopy were not considered by NPE. Even 
though similar studies had been done before, we were asked to clarify the issue of 
insurance of our intended participants. This process took about a year, including much 
correspondence. Our study, among others, eventually brought about a clarification of this 
issue, and now healthy research subjects are considered in NPE. 
 
5.2. Methodological considerations 
5.2.1. Study design 
Both the questionnaire survey in 1987 by Bernersen and co-workers, as well as the 
survey including H. pylori testing in 2004, were done in a cross-sectional population-
based design. The endoscopy survey in 1987 had a case-control design with subjects 
suffering dyspepsia being cases [30]. This caused some restrictions in further analyses 
and interpretations of results. First, the analyses of changes in the prevalence of H. pylori 
had to be stratified by dyspepsia. Second, there is a potential selection bias in the sense 
that the prevalence of H. pylori infection in the cohort that we have followed was 
somewhat higher than expected in the general population. In 2004, we found an overall 
age-adjusted prevalence of H. pylori of 25 % in both men and women (Paper III). For the 
sake of comparison, we have estimated the overall prevalence of H. pylori in 1987. The 
age adjusted prevalence of H. pylori in subjects (both genders) with dyspepsia in 1987 
was 48.0%, and a corresponding 36.3% in subjects without dyspepsia [34]. The age 
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adjusted prevalence of dyspepsia in 1987 (both genders) was 29.3%. An estimate of the 
overall prevalence of H. pylori infection in 1987 was thus 39.7% 
( )707.0*%3.36293.0*%0.48 + . 
At the start of the endoscopy examinations in 2004, we had limited time, as the 
endoscopy unit in Sørreisa was planned to be functioning for three months only. We 
therefore started by inviting those who had undergone endoscopy in 1987, parallel to 
sending out the questionnaire. We were surprised to find that the willingness to undergo 
endoscopy was higher than the willingness to answer the questionnaire in this cohort. We 
have thus 38 subjects who had endoscopy in 2004 without answering the questionnaire. It 
was less surprising that 240 chose to answer the questionnaire without providing stool 
samples. Only 10 subjects sent stool samples for H. pylori detection without further 
participation. This is probably explained by losing or forgetting the questionnaire, but 
misclassification of identification in the laboratory is also a possibility, which occurred in 
a few cases. 
 
 5.2.2. Bias 
Bias can be defined as a systematic error seen when a risk factor or a characteristic 
applies unequally to comparison groups and thus distort the results [35;36]. Bias should 
always be considered as an alternative explanation of a finding.  
 
5.2.2.1. Selection bias 
If the population enrolled in the study differs in a characteristic way from the population 
not enrolled we may encounter selection bias [35;36]. Beside the geographical location of 
our study in the municipality of Sørreisa, the only selection criterion of our study subjects 
was age between 18 and 85 years. A study focusing on gastrointestinal complaints may 
be more appealing to subjects suffering dyspeptic symptoms than to those without 
symptoms, a phenomenon called self-selection. A study of non-participants could clarify 
if selection bias is present, but this can only be done if information from registers is 
available. In our case this would mean a need for information about peptic ulcer, gastro 
oesophageal reflux disease (GORD), use of anti-secretory medication and other specific 
diagnoses, as well as the use of health services. Such information from health registers 
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did not exist in Norway in 2004. We have studied non-participants regarding their age 
and gender distribution, and could not find differences in the age distribution between 
those who accepted gastroscopy and those who only answered the questionnaire. Men 
and women were equally represented in the upper endoscopy examinations. Dyspepsia 
was reported by 33.2% of the questionnaire responders and 37.6% of the participants of 
the endoscopy examinations, a non-significant difference of proportions. The proportions 
of women who answered the questionnaire and sent stool samples were somewhat higher 
than the corresponding proportion of men. Predominance of women in health surveys is 
common [37-39]. Some argue that in epidemiologic studies in general, non-participants 
have a lower socioeconomic status than participants [40]. Others argue that in a country 
such as Norway with a small social gradient, and the availability of a personal 
identification number enabling the study population to be unbiased a priori, no major 
source of selection bias is expected in a population-based study [41]. As seen from 
figures 3-5 the patterns of participation are very similar in the various parts of the study. 
The slightly higher proportion of women participating is not believed to interfere with 
our results.  In addition, we have presented our analyses stratified by gender, or 
incorporated gender in the analyses. The overall response rate of the survey in Sørreisa 
was 40%, which is further discussed in section 5.3. 
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Figure 3. Age distribution (%) of participants and non-participants of the questionnaire 




Figure 4. Age distribution (%) of participants and non-participants of the H. pylori testing 
in 2004. Ten years intervals. 
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Figure 5. Age distribution (%) of participants and non-participants of the endoscopy 





5.2.2.2. Information bias 
If measurements of risk factors or outcome differ between comparison groups we 
encounter information bias [35]. Measurement error is a subtype of information bias. All 
analyses of stool samples were done by the same two persons using the same techniques 
for all participants. All histological examinations were done by one pathologist who also 
re-examined the histology slides from 1987. All endoscopy examinations in 2004 were 
done by this author. The questionnaire was the same for all participants. In the cross-
sectional part of the study we have not found sources of information bias. In the follow-
up study we have differential classification of H. pylori, as the diagnosis was done with 
different methods in 1987 and in 2004. We have considered this when comparing results 
from 1987 and 2004 (thoroughly discussed in Papers III and IV). Method of assessment 
of H. pylori should not bias the results in the analyses restricted to either 2004 or 1987. 
The questions on dyspepsia were the same at both times. Peptic ulcer was partly self-
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reported and partly diagnosed at endoscopy. Self-reporting involves a risk of recall bias, 
as persons suffering the outcome (ulcer) tend to remember risk factors (dyspepsia, 
smoking) better than healthy persons do [36]. In our case risk factors were measured 
ahead of outcome, and the cohort design as used in our study, is thus more resistant to 
recall bias. When comparing findings at endoscopy between 1987 and 2004 we may be at 
risk of measurement bias as the examinations were performed by two physicians. The 
study of observer-variation reveals a high degree of disagreement in endoscopy, and in 
consequence of this we have simplified endoscopic findings in our analyses 
(dichotomized the findings of oesophagitis), and chosen distinct findings (absence or 
presence of peptic ulcer) as outcome variables. 
 
5.2.3. Confounding and interaction 
Confounding is present when a statistically significant association between a risk factor 
and outcome under study is causally explained by another factor that is also associated to 
the risk factor under study [35]. The causal factor is the confounder, and the apparent 
association between the risk factor and outcome under study is said to be confounded. 
The confounder can explain all or some of the observed association. In our study (Paper 
IV) we found a difficult financial situation to be associated with peptic ulcer in 
univariable analysis. Several other studies have also reported socioeconomic difficulties 
to be associated with peptic ulcer and/or dyspeptic symptoms [42-44] However, it is 
difficult to imagine a direct causal relationship. There are various strategies to deal with 
presumed confounding. We have used multivariable regression, in which the effects of 
the risk factors entered into the model are adjusted for the effect of the other risk factors 
or potentially confounders entered in the model[33]. In the multivariable regression 
model the apparent risk for peptic ulcer associated with a difficult financial situation 
disappeared. This was also the case for the use of antacids, which in univariable logistic 
regression analysis was positively associated with peptic ulcer, whereas it in 
multivariable logistic regression analysis was not. We thus have employed strategies to 
reveal confounding, but we can never know if we have considered all potential 
confounders. Regression models are limited to what one chooses to enter, a choice that 
should always be open for discussion.  
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Interaction is the case when two causal risk factors interact, in the way that the effect of 
one risk factor differs with different levels of the other [45]. We found interaction 
between H. pylori and gender in the analyses of risk of peptic ulcer in Paper IV. H. pylori 
was a much stronger risk factor for peptic ulcer in men than in women. If interaction is 
present, results should be presented stratified by one of the interacting risk factors, which 
is why we have presented the results stratified by gender. When we stratify, the groups 
and the number of outcomes get smaller which results in loss of power. In Paper IV, the 
number of peptic ulcers among women was as low as 6. The cumulative prevalence of 
peptic ulcer was 4.8% (n = 4) in women with H. pylori and 2.6% (n = 2) in women 
without H. pylori. Power calculations revealed that we would have needed 2000 women 
in the study to prove that the observed difference in prevalence was significant, with a 
power of 0.8 and an α level of 0.05. 
 
5.2.4. Challenges in follow-up 
For practical and formal reasons our follow-up could only include persons still living in 
the municipality of Sørreisa, the practical reason for this being the location of the 
endoscopy unit. This was only partly a limitation, as many of the 121 subjects that had 
moved had not moved far and could have been easily enrolled. The formal reason was 
that the license to register persons given to us by the Norwegian Data Inspectorate, was 
limited to persons living in Sørreisa.  
 
5.3. Helicobacter pylori  testing;  feasibility 
The assessment of H. pylori infection was essential to the study. We decided early on a 
cross-sectional design of testing for H. pylori linked to the questionnaire, and was thus 
challenged to use a non-invasive and accurate test. Serology is a sensitive diagnostic 
method with a too low specificity [46], and would also present logistic challenges in 
obtaining, storing, and transporting blood samples. Urea breath test using a C13 isotope 
was too costly, whereas using the C14 isotope, which at the time was the standard 
procedure at the University Hospital of North Norway, was not an option as this 
radioactive isotope could not be sent by mail.  
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Antigen testing in stool samples was a fairly new method in 2003. We thought this test 
could be useful in our study, and decided to do a local validation of a commercial kit, the 
Amplified IDEIA Hp StAR®. With this sub-study we hoped to assess the technical 
performance of the test, and to become familiar with the logistics of laboratory analysis. 
In addition, we wanted to learn how patients complied with taking and sending stool 
samples, which one could expect some to be reluctant to do. We could not systematically 
register if patients were not enrolled due to reluctance of sending stool samples, as the 
patients were not asked to give a reason for refusing enrolment for ethical reasons. This 
has implications for our appraisal of compliance with the test, but does not alter the 
analyses of test performance. 
The major reasons for not enrolling intended patients in the validation study of the stool 
test was logistic, as the study was part of the daily routine, and some days in the 
outpatient department were too busy too enrol patients. All together 10 of 131 subjects 
enrolled in the study failed to send stool samples, a drop-out rate of 7.6% which is not 
more than expected in a clinical study. After validation, the test was taken into clinical 
use. The technical performance of the test was excellent, as presented in Paper I. 
Although compliance could not be quantified, our experience from the study and 
subsequent use of the test in clinical practice was that compliance was good. We 
therefore considered it feasible to take it into use in the population-based study.  
Unfortunately the response rate was markedly lower than we had hoped for. Part of the 
explanation of this may be attributed to the stool test, as we heard comments about it in 
Sørreisa at the time of the study. The response rates were lowest in the youngest and the 
oldest age groups.  The overall response rate of about 40% was low compared with 
another population-based study in the same region, the Tromsø VI study (ongoing 
2007/2008) that has a response rate of somewhat more than 60%. However, a population-
based study in Bristol, UK, detecting H. pylori using a C13 urea breath test, report similar 
response rates [47]. Taking into account the discomfort experienced by the responders, of 
taking and sending stool tests, we found the response rate acceptable.  
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5.4. Gastroscopy    
As with most diagnostic procedures, endoscopy has been taken into clinical use in patient 
populations without a prior systematic validation of technical and diagnostic 
performance. When discussing management strategies of dyspepsia and H. pylori, 
endoscopy is one of the options, and for this reason it is appropriate to reflect upon the 
observer variation of endoscopy. OMED has addressed the issue of standardisation and 
documentation of endoscopy reports in an attempt to render possible exchange of 
information worldwide [29]. 
Our study revealed extensive, but not surprising, variation in the assessment of 
endoscopy images. Studies of observer variation in endoscopy and other diagnostic 
disciplines show similar results [24;25], though some are more optimistic regarding 
agreement [48;49]. When examining highly prevalent conditions as dyspepsia and the 
presence of H. pylori, it is important to be aware of the limitations of the diagnostic tools, 
and this should be considered when discussing management strategies. 
The high degree of observer variation had implications for our study, as it made us 
cautious in the interpretations of endoscopy findings. We have chosen outcome 
parameters based on more distinct findings, such as the presence or absence of peptic 
ulcer and the presence or absence of oesophagitis, rather than non-distinct observations 
such as endoscopy features of gastric inflammation or grades of erosive oesophagitis  
 
5.5. Risk factors 
A risk factor in epidemiology is a condition or characteristic associated with, but not 
necessarily causing a disease. In our study the risk factor of main interest was H. pylori, 
with a prevalence of around 25 % in 2004 and 40% in 1987. There are many strains of 
this bacterium, and some strains are characterized by qualities connected to a higher 
degree of pathogenesis than others [50]. One may argue that H. pylori is part of the 
normal flora with a potential of pathogenesis. This view is supported by the fact that 
other mammals also host Helicobacter species [51;52].  
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There are indications that H. pylori, or its ancestors, have been with us since before we 
evolved as homo sapiens, and there is support for the view that it has both beneficial and 
harmful effects to humans [53]. Some beneficial effects believed to be associated with 
carrying H. pylori are a lower risk of asthma and diarrhoea, a positive modulation of the 
energy balance, and a lower risk of GORD, though the latter is controversial [54;55]. The 
recognised harmful effects are peptic ulcer disease [56], gastric adenoma [57] and 
mucosa-associated lymphoid tissue (MALT) lymphoma [58].   
We found male gender to be associated with an increased risk of peptic ulcer as well as 
oesophagitis. When studying gender differences in health, differences in behaviour 
regarding presentation of symptoms and use of health services between men and women 
must be considered. This is a challenge in patient populations, as they are a priori 
selected on the basis of symptoms and behaviour. Gender specific symptom presentation 
and behaviour patterns are clinically important and studies of patients are of great value. 
In contrast, population-based studies add information which, to a certain extent, 
disregards such conditioned behaviour. Our finding of an increased risk of oesophagitis 
and peptic ulcer in men should thus reflect real gender differences (further discussed in 
Section 5.8). 
The relationship between ASA and NSAID use and H. pylori as risk factors of peptic 
ulcer disease has been considered in many studies, with reviews and meta-analyses 
concluding that they are independent risk factors with a synergistic effect [56;59]. 
Smoking is a major challenge to public health, and the gastrointestinal tract is also a 
target for the harmful effects of smoking [11]. We found support for smoking being an 
independent risk factor for peptic ulcer, with an odds ratio of  2.19 (Paper IV). In a meta-
analysis from 1997, Kurata and Nogowa reported smoking to have a relative risk of about 
2.2 and H. pylori to have a relative risk of about 3.3 regarding peptic ulcer disease [60]. 
Our findings may reflect a decreasing role of H. pylori, relative to that of smoking. 
Whereas the prevalence of H. pylori seems to decrease spontaneously with improved 
hygienic standard, efforts are still needed for the prevalence of smoking to decrease. 
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5.6. Dyspepsia from a public health perspective 
A major challenge in the discussion of dyspepsia is its definition. In the Sørreisa study we 
used a low threshold definition covering a long time span in both the 1987 and the 2004 
surveys (“the Sørreisa definition”). In addition, a graded definition covering a short time 
span (the GSRS) was used. The GSRS is a validated questionnaire on gastrointestinal 
disorders, asking for symptoms during the last week. As such, the Sørreisa dyspepsia 
criteria are not easily translated into the GSRS score. We considered other validated 
questionnaires such as the Reflux Disease Questionnaire (RDQ) [61], the Quality of Life 
in Reflux and Dyspepsia (QOLRAD) [62] and the commonly used Rome Criteria (Rome 
II Criteria at the time of our planning) [63]. The Rome criteria cover a longer time span 
than does the GSRS, but a shorter time span than the Sørreisa definition. We chose the 
GSRS scale as it measures the point prevalence of dyspepsia within the last week, and 
thus complements the “life time” prevalence of the Sørreisa definition of dyspepsia. The 
overall score of the GSRS scale is an average of the score of the 15 questions included. 
In Paper III, the GSRS questions were divided into five dimensions (abdominal pain, 
indigestion, reflux, constipation, and diarrhoea) and dichotomised. The prevalence’s of 
the various dimensions were given. These dimensions were a composite of the GSRS 
questions included. A positive score was defined if at least one of the questions were 
equal to, or higher than 3. This is a somewhat different approach than used by others, as 
the GSRS dimensions are normally calculated by an average of the included questions. 
The GSRS questions about acid regurgitation and heartburn are somewhat similar and 
both measures of gastro-oesophageal reflux symptoms. 
Our way of coding the GSRS reflux dimension, resembles the Sørreisa definition better, 
but makes comparison with other studies a little more obscure.  
Table 1 shows the measured agreement between the Sørreisa question and the GSRS 
questions on reflux symptoms. “GSRS reflux syndrome” in the table is a combination of 
“acid reflux” and “heartburn”, with a combined score equal to the higher of the two. 
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Table 1. Agreement between Sørreisa reflux symptoms and reflux syndrome on the 
gastrointestinal symptoms rating scale. 
  GSRS reflux syndrome 
  1 2 3 4 5 6 7 
No 555 116 49 3 0 0 0 
Sørreisa Reflux 
Yes 122 78 113 34 3 5 0 
 
 
When the GSRS categories 1-2 and 2-7 of the GSRS are pooled and dichotomised as 
described above and presented in table 2, we find moderate agreement (κ = 0.40) with the 
Sørreisa definition of reflux [32;33]. 
 
Table 2. Agreement between Sørreisa reflux symptoms and GSRS reflux syndrome on a 
dichotomous scale. 
  GSRS Reflux Syndrome 
  No Yes 
No 671 52 
Sørreisa Reflux 
Yes 200 155 
 
 
The GSRS does not include questions on upper abdominal pain, and comparison with the 
Sørreisa question on this subset of symptoms is encumbered with too much uncertainty. 
All assessment methods of dyspepsia have much of the same shortcomings, due to the 
heterogeneity of symptoms that is often seen in the same patient. Our low threshold 
questions in the Sørreisa definition cover a broad spectrum of upper abdominal 
symptoms. As the public health care consequences are much the same for all subgroups 
of patients with upper GI symptoms, i.e. referral to endoscopy or prescription of anti-
secretory medication, we believe our definition to give a realistic measure of the burden 
of dyspepsia. Information on the use of health services and medications should also be 
taken into consideration, which is discussed below. 
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Other studies report prevalence of dyspepsia between 10 and 40% [13;64;65]. These 
numbers seem unaltered during the last decades, and the uniformity of the prevalence of 
dyspepsia with different definitions is more striking than the differences [64].  
Trying to differentiate dyspeptic symptoms into ulcer-like and reflux-like is difficult as 
symptoms overlap, and are prone to change over time [66;67]. In addition, symptoms 
give a poor prediction of organic disease [68].  
The high prevalence of dyspepsia makes it an important public health issue. At the same 
time it is important to remember that in the vast majority of patients, dyspepsia is a 
benign condition [64;69]. In our study, about 32% suffered dyspeptic symptoms using the 
Sørreisa definition. All together 37% of these had seen a specialist in gastroenterology 
due to their dyspeptic symptoms sometime during the follow-up period, and 31% had 
seen their general practitioner during the last year for the same reason (unpublished data).  
Medications for dyspepsia have undergone an impressive development during the last 20 
years. Antacids have been available for decades. In the eighties, the H2-receptor 
antagonists were introduced, and the latest contribution is the family of PPI. In Norway 
the use of PPIs is high and increasing, whereas the use of the other acid inhibiting drugs 
is quite stable (Table 3.). 
 
Table 3. Sales of drugs for acid-related disorders and sales of ulcerogenic drugs.  
DDDa/1000 inhabitants/day in Norway 





1995 4.9 6.7 4.5 45.4 24.6 
2000 3.3 5.9 14.7 48.7 33.8 
2005 2.1 5.5 24.5 66.5 43.9 
2006 2.0 5.7 27.1 69.4 45.3 
2007 1.9 5.8 29.8 72.9 46.4 
aThe Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a 
drug used in its main indication in adults. http://www.whocc.no/atcddd/ 
bIncluding other platelet aggregation inhibitors, but not heparin  
Extract from http://nomesco-da.nom-nos.dk/filer/publikationer/Helse%202006.pdf [70] 
 - 36 - 
 
From the individual patient’s view, it is reassuring that very efficient drugs for treating 
dyspepsia are available. From a public health view it is adequate to question if the most 
expensive and efficient drugs should be our first choice in cases of dyspepsia, or whether 
we can somehow reach our goal by the use of cheaper and less efficient drugs, which 
may be good enough.  
Still, dyspepsia occupies a large amount of health resources, and there is an ongoing 
debate of how to manage dyspepsia rationally and cost-beneficially [71;72].  
 
5.7. Helicobacter pylori from a public health perspective 
Most of the research on H. pylori infection has been done in patients suffering dyspepsia 
or peptic ulcer disease. Population-based studies are needed for a public health 
perspective on these issues. If every person hosting H. pylori should be considered 
infected, i.e. being a patient,  then H. pylori infection, with a prevalence of 25%, is a 
major public health issue. However, the diseases linked to H. pylori are not common in 
our part of the world. The incidence of gastric cancer is decreasing (Figure 6). We do not 
have data from health registers on the incidence and severity of peptic ulcer disease in 
Norway, but a previous study from Northern Norway from 1984 reported incidence rates 
of duodenal and stomach ulcers of 1.4 and 0.8 per 1,000 per year [73], which corresponds 
very well with earlier Danish reports [74;75]. In Denmark, the incidence of duodenal 
ulcers is decreasing [76], a trend believed to apply to Norway as well, where a decreasing 
incidence of perforated peptic ulcers has been reported [77]. 
MALT lymphoma, which is strongly associated to H. pylori, is a very rare disease with 
9.4 new cases in Norway every year (Incidence; 0.21/100 000/year) [78], and thus not a 
public health issue. 
 
Treatment of H. pylori is a potentially important issue implicating the use of two or three 
different, broad spectrum antibiotics. The indigenous bacterial flora is also affected 
during such treatment, with the potential of selection and persistence of resistant strains 
[79], contributing to future problems of spread of infections with resistant bacteria.  If we 
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do not apply strict clinical indications for antibiotic treatment, we could face a serious 
overuse, bearing in mind that 25% of the population host H. pylori and 32% suffer 
dyspeptic symptoms from time to time independent of this. In central parts of Europe and 
in the USA, a “test and treat” strategy is recommended [17]. We do not find any support 
for such a strategy in our study due to the lack of association between dyspeptic 
symptoms and H. pylori.  
In other parts of the world the epidemiology of H. pylori and gastric cancer differs very 
much from here, and our results would apply for our region only. In Asia H. pylori is 
highly prevalent and gastric cancer far more common than in Europe and North America 
[80]. Japan and Korea have the highest incidence of gastric cancer with rates in the range 
of 50-80/100 000/year in men, and 20-30/100 000/year in women. Northern Europe have 
some of the lowest incidence rates worldwide; about 5/100 000/year in women and 11/ 
100 000/ year in men [81]. As the premises differ, the strategies of dealing with H. pylori 
should be adapted to regional epidemiology. 
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Figure 6. Five-year age adjusted incidence (per 100 000) of gastric and oesophageal 
cancer in Norway.  
 
From The Norwegian Cancer Registry.  www.kreftregisteret.no  
 
5.8. Endoscopy findings in a general population 
5.8.1. Peptic ulcer 
In 2004 we found 19 subjects with peptic ulcers at endoscopy (Table 4) compared with 
15 subjects in 1987 (Table 5). The numbers of ulcers are too low to say something 
definite about changes in prevalence of peptic ulcer disease, especially considering the 
inter-observer variation in endoscopy. However, we can address the distribution between 
stomach and duodenal ulcers, the gender-specific distribution and the role of H. pylori. 
In 2004 there were almost twice as many gastric as duodenal ulcers (Table 4), whereas in 
1987 there was a more even distribution of stomach and duodenal ulcers (Table 5) 
(unpublished data). H. pylori was present in almost all cases of duodenal ulcers at both 
times, whereas in gastric ulcers, H. pylori was dominant in 1987 but only present in about 
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50% in 2004. This could imply that peptic ulcer disease is becoming more dominated by 
gastric ulcers, and that the role of H. pylori is on retreat. Other reports indicating that 
duodenal ulcers are strongly associated with H. pylori, whereas the association to gastric 
ulcers is not as close support this [82;83]. As discussed above, peptic ulcer disease is 
often reported as a predominantly male disease. In Sørreisa in 2004 we can confirm that 
the prevalence of peptic ulcer disease is higher in men than in women, as only 4 of 19 
subjects with ulcer were women (p=0.01).  In 1987 the gender distribution of peptic ulcer 
disease was more even.   
 
Table 4. Localisation of peptic ulcers at endoscopy in 2004 
  Duodenal ulcer  
  Yes No Total
Yes 1 12 13a  
Stomach ulcer 
No 6 543 549 
 Total 7b 555 562 
a 6 Hp +ve, 5 Hp –ve (2 missing values of Hp)   7 men, 4 women. ¨ 
b All men, all Hp +ve 
 
Table 5. Localisation of peptic ulcers at endoscopy in 1987 
  Duodenal ulcer  
  Yes No Total
Yes 0 8 8 a 
Stomach ulcer 
No 7 604 611 
 Total 7 b 612 619 
a 7 Hp +ve, 4 men, 4 women. 
b 6 Hp +ve, 3 men, 4 women 
 
5.8.2. Oesophagitis 
The high inter-observer variation in assessing oesophagitis (Paper II) makes comparison 
between 1987 and 2004 difficult. In addition, oesophagitis was assessed with the Savary-
Miller classification in 1987 [84] and with the Los Angeles Classification [48] in 2004. 
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However, it is interesting to see that at both times oesophagitis was more prevalent in 
men than in women. In 1987 the prevalence of oesophagitis was 13.4% (95% CI 9.8%-
17.0%) in men, and 5.9% (95% CI 3.1%-8.8%) in women, whereas in 2004 the 
prevalence of oesophagitis was 30.6% in men (95% CI 25.2%-36.0%) in men, and 14.3% 
(95% CI 10.3%-18.3%) in women (the numbers are age adjusted using the joint study 
population at each time as standard population). A predominance of oesophagitis in men 
is also known from meta-analyses of patient populations [85]. There is accumulating 
evidence that increasing body mass index (BMI) is a risk factor of GORD [86;87], and 
some, but sparse, evidence that weight loss may  improve gastro-oesophageal reflux 
symptoms [88]. In our follow-up analysis of the cohort of endoscopy participants from 
1987 we have examined BMI as a possible risk factor for oesophagitis, without finding 
BMI in 1987 to affect the presence of oesophagitis in 2004. The relationship between 
oesophagitis and BMI is better addressed in a cross-sectional study, as a risk factor as 
high BMI should be present when measuring its effect. 
 
5.8.3. Morphological changes in the gastric mucosa 
 In 1987 75% of the subjects had some pathological finding in the gastric mucosa (92% in 
H. pylori positive and 40% in H. pylori negative), compared with 66% in 2004 (95%  and 
59%, respectively) This is based on assessment by the same pathologist. The numbers are 
age adjusted using the joint study population at each time as standard population. Hosting 
H. pylori was followed by some degree of gastric inflammation in almost all cases. 
However, about half the subjects without H. pylori also showed some degree of 
morphological changes. The question of what features to be found in a “normal” gastric 
mucosa is still open for discussion [89]. Our most important finding regarding 
morphological changes in the gastric mucosa is probably that the most chronic lesions 
may be initiated by H. pylori, but that elimination of this infection does not result in 
regression of the lesions. 
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6. IMPLICATION FOR CLINICAL PRACTICE AND FURTHER 
RESEARCH  
  
Detection of H. pylori in stool samples is a convenient and accurate diagnostic method, 
suitable for an outpatient setting. Its use in a population-based study will imply a trade off 
between the benefit of it being an accurate test, with the risk of low participation due to a 
reluctance to provide stool samples.  
During the last decades, we have seen a decreasing prevalence of H. pylori parallel to a 
decreasing incidence of gastric cancer and peptic ulcer disease. At the same time we have 
seen a persistent high prevalence of dyspepsia.  
From a public health view, H. pylori today plays a decreasing role in our part of the 
world, whereas dyspepsia is still a major burden of health, generating high expenditures 
and use of health services. We are in need of rational strategies for the management of 
dyspepsia. Such strategies should probably not include treating H. pylori, in the absence 
of other symptoms or findings than dyspepsia, as the association between dyspepsia and 
H. pylori is unclear in our region. We should rather balance costs of health care services 
associated to dyspepsia against its rather benign nature. 
Further validation of the benefit of endoscopy, especially in patient populations with less 
severe symptoms, seems appropriate. 
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ERRATA 
The numbers in Figure 1 differs slightly from the flowchart in Figure 1 of Paper III. 
Invited population in 1987 was 2391, and not 2385 as stated in the paper. The numbers of 
responders are correct, but include only subjects <70 years old, as only these were 
included in the original publications from the study in 1987. 
In 2004 1145 subjects answered the questionnaire and not 1143 as stated, a difference 
due to misclassification of attendance.  
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En studie om mageplager i en befolkning
Forespørsel om deltakelse i forskningsprosjekt
(voksen 18-85 år)
Fordøyelsesbesvær eller magesårsliknende plager er svært vanlig. I 1987 ble det gjort en stor undersøkelse  
om slike plager i Sørreisa kommune. Vi skal nå gjøre en ny undersøkelse for å studere utviklingen av 
mageplager siden 1987.  Hovedformålet med denne undersøkelsen i Sørreisa er å skaffe ny kunnskap om 
mageplager for å kunne forbedre behandlingen av dem.
Helseundersøkelsen i Sørreisa er godkjent av  Datatilsynet. Regional etisk komite for medisinsk 
forskningsetikk har vurdert studien og har ikke innvendinger mot gjennomføringen.
All deltakelse i forskningsprosjektet er frivillig, og du kan trekke deg fra undersøkelsen til enhver tid uten 
begrunnelse. Om du ikke ønsker å delta eller om du trekker deg vil det ikke få noen konsekvenser for 
forholdet til helsevesenet.
I tillegg til opplysningene om mageplager som du gir i  spørreskjemaet ønsker vi å kunne hente 
opplysninger om mageplager som finnes i din journal på legekontorene i Sørreisa og i eventuell 
sykehusjournal. For de som deltok i Sørreisaundersøkelsen i 1987 ønsker vi å  undersøke innsamlet 
materiale fra den gang på nytt, og sammenholde det med resultater fra Sørreisaundersøkelsen  i 
2003. For de som ikke samtykker til dette, vil tidligere data bli anonymisert. I prosjektet ønsker vi å 
undersøke avføringsprøver for å se på forekomsten av forskjellige bakterier og parasitter, deriblant 
magesårsbakterien Helicobacter pylori, og deres følsomhet for antibiotika. Til dette trenger vi en 
avføringsprøve slik det er angitt på vedlagte prøveglass.
En del personer vil også bli forespurt om å la seg undersøke med gastroskopi (kikkertundersøkelse av 
magesekken) og blodprøve i Sørreisa. Hvis du ikke ønsker å gjennomgå gastroskopi og gi vevsprøve og 
blodprøve, kan du likevel delta i spørreundersøkelsen.
Innsendte spørreskjemaer og avføringsprøver vil bli gjennomgått av prosjektleder eller medarbeidere, 
og vil bli  behandlet strengt fortrolig. Alle innsamlete opplysninger og prøver oppbevares og analyseres 
i 15 år, hvor personidentifikasjon er erstattet med registreringsnummer. Dette nummeret viser til et 
personregister som oppbevares adskilt fra det øvrige materialet. Dataregistrering og oppbevaring 
er godkjent av datatilsynet. All bruk av opplysninger og prøver vil bare skje etter godkjenning fra 
Datatilsynet og såfremt Regional komite for medisinsk forskningsetikk ikke har innvendinger mot det. 
Du har innsynsrett i opplysninger som registreres om deg.  Om du trekker deg fra undersøkelsen kan du få 
allerede innhentede data slettet.
Resultater av studien vil bli publisert i medisinske tidsskrift og et sammendrag vil bli presentert i lokale 
medier. Alle resultater presenteres på en slik måte at ingen enkeltpersoner kan kjennes igjen.
Vi ber deg om å bekrefte om du ønsker å delta i prosjektet ved å fylle ut og underskrive 
samtykkeerklæringen på neste side.
– 1 –
Sted: ..................................................................................................................        Dato:…………………………………….
Navn (blokkbokstaver): ....................................................................................
Underskrift: ......................................................................................................
Avføringsprøven tatt: Dag ...............  /Måned ...............  /År ........................
Sendes inn snarest mulig i vedlagte konvolutt av hensyn til holdbarhet. Portoen er betalt.
Skjemaetleses maskinelt. Vennligst skriv innenfor rutene.
Du kan ta vare på den løse kopien av dette skrivet som ditt eget.
Har du spørsmål kan du ringe tl. 99 40 63 83.
Med vennlig hilsen
                      Anne Mette Asfeldt                              Eyvind Paulssen                                                Bjørn Straume
                                   Lege                                                Overlege                                                      1. amanuensis
                   Institutt for klinisk med.                      Gastromedisinsk avd.                              Institutt for samfunnsmedisin
                                   UiTø                                                     UNN                                                                 UiTø
Spørreskjema og avføringsprøve:
Jeg har lest informasjonen i forespørselen og sender herved 
utfyltspørreskjema og avføringsprøve. 
                                                         Ja   Nei  
(Hvis du ikke ønsker å besvare spørreskjemaet, og vil unngå 
purring, kan du sette kryss i ”Nei” ruten og sende skjemaet 
i retur)
                                                        
Hvis du samtykker i å delta i spørreundersøkelsen, vil vi be 
deg om i tillegg å bekrefte eller avkrefte, om du ønsker å 
delta i de forskjellige delene av prosjektet, slik de er beskre-
vet nedenfor.
                                                        
Journalopplysninger:
Jeg samtykker i at opplysninger om mageplager og 
undersøkelser/behandling for disse kan innhentes hos 
primær-/fastlege og hos sykehus.
                                                         Ja   Nei   
Ny kontakt:
Jeg samtykker i å eventuelt bli kontaktet i fremtiden med 
forespørsel om nye opplysninger eller undersøkelser om 
mageplager, hjerte eller lungesykdommer, kreftsykdommer 
eller spørsmål om livsstil.                  
                                                            
                                                         Ja   Nei  
                                                        
Kobling av data:
Jeg samtykker i at resultatene mine, etter godkjenning
fra datatilsynet, kan settes sammen med opplysninger om 
meg i andre registre til bruk i medisinsk forskning om mage-
plager. Det kan være registre om helse, trygd og sykdom. 
Det kan også være registre om  inntekt, utdanning og yrke.  
Eksempler på slike registre er Kreftregistret, Døds-
årsaksregistret og folketellingene.
I disse tilfeller blir navnet og personnummeret mitt fjernet 
når dataene blir analysert.
                                                         Ja   Nei  
Sørreisa I:
Jeg deltok i Sørreisaundersøkelsen i 1987 og samtykker i, at 
resultatene mine og innsamlet prøvemateriale fra den gang 
undersøkes på nytt.                        
                                                         Ja   Nei  
SAMTYKKEERKLÆRING
– 2 –
Den første del av spørreskjemaet handler 
om livsstil, levekår og helse generelt.
1. Hvor er du født?
1  Norge 2  Europa
3  Nordamerika 4  Resten av verden
2. Hvor er dine foreldre født?
1  Norge 2  Europa
3  Nordamerika 4  Resten av verden
3. Bodde du i Sørreisa kommune i 1987?
1  Ja 2  Nei
4. Deltok du i Sørreisaundersøkelsen i 1987? (Sett evt. flere kryss)
0  Ja, besvarte spørreskjema
1  Ja, ble undersøkt med gastroskopi
2  Nei, deltok ikke
5. Har du vært i utlandet siste månenden?
1  Ja 2  Nei
Andre helseforhold
6. Har du eller har du hatt kreftsykdom?
1  Ja 2  Nei
Hvis “Ja”  Hvor i kroppen  
                      Hvilket år ble den oppdaget  
                      Ved hvilken institusjon ble den påvist  
7. Er du operert i magen?
1  Ja 2  Nei
Hvis “Ja”  Av hvilken årsak  
                      Ved hvilket sykehus 
                      I hvilket årstall 
9.  Hvordan er helsen din nå? (Sett ett kryss)
1  Dårlig
2  Ikke helt god
3  God
4  Svært god
10. Oppgi din høyde og vekt nå
                     Høyde uten sko  cm
                     
                      Vekt uten klær  kg
11. Hvilket nummer er du i rekken av søsken? (Eksempel; Hvis 
søskenflokken består av 2 storebrødre, deg og  lillesøster blir du nummer 3 
av 4. Tell også med søsken som er døde)
 Nummer    av   
12. Hvor mange nålevende søsken  har du?
 Antall 
13. Har noen av disse i din familie hatt magesår? 
1  Ektefelle/samboer 5  Bror
2  Mor 6  Barn
3  Far 7  Ingen
4  Søster 8  Vet ikke
14. Angi, såfremt du kan, om du som barn fikk:(Sett bare ett kryss)
1  Brystmelk 
2  Kunstig ernæring (flaske)
3  Begge deler
4  Vet ikke
15. Hvor ofte har du mosjonert eller deltatt i fysisk trening av 
minst 20 minutters varighet og slik at du blir svett eller 
andpusten? (sett kryss for hver alder)
1 Sjelden 
eller aldri
2 Ukentlig 3 Flere gang-
er i uken
4 Daglig
15.1  Som 15 åring
15.2  For 5 år siden
15.3  For tiden
Alkohol
17. Hvor ofte drikker du øl, vin eller brennevin?
1  Sjeldent eller aldri
2  Omtrent 1 gang i måneden
3  2-3 ganger i måneden
4  Omtrent 1 gang i uka
5  2-3 ganger i uka
6  Omtrent daglig
– 3 –
18. Hvor mange gjenstander drikker du i gjennomsnitt på en 
dag hvor du drikker? (gjenstander defineres som: glass øl på 0.33 l, 
vanlig glass vin på 1.4 dl eller vanlig glass brennevin på 40 cl. Skriv samlet  
antall gjenstander)
 Antall gjenstander 
19. Omtrent hvor mange ganger i løpet av det siste året har 
du drukket så mye som minst 5 glass eller drinker i løpet 
av et døgn? 
 Antall ganger  
Tobakk
20.  Hvor mange sigaretter (filtersigaretter og/eller rullings) 
røyker du  daglig?
 Skriv 0 hvis du ikke røyker sigaretter
 Antall  
21. Hvor mange esker snus eller skråtobakk bruker du  
ukentlig?  Skriv 0 hvis du ikke bruker noe 
 Antall  
22. Hvor mange piper røyker du  daglig?
 Antall  
Medisin
23. Bruker du flere ganger i uken en eller flere av følgende 
medisiner: Albyl E, Plavix, Asasantin, Aspirin, Dispril, Globoid?
1  Ja 2  Nei
24.  Bruker du flere ganger i uken en eller flere av føl-
gende medisiner: Confortid, Indocid, Clinoril, Cataflam, 
Diclofenac, Modifenac, Otriflu, Voltaren, Toradol,  Barcan,  
Arthrotec, Brexidol, Felden, Pirox, Piroxicam, Tetram, 
Mobic, Brufen, Ibumetin, Ibuprofen, Ibux, Alpoxen, Ledox, 
Napren, Napren-E, Naprosyn, Naprosyn Entero, Naproxen, 
Naproxen-E, Ketoprofen, Orudis, Migea, Celebra, Vioxx?
1  Ja 2  Nei
25. Har du i løpet av de siste 3 måneder brukt penicillin eller 
andre antibiotika
1  Ja 2  Nei
Hvis ja, angi dato
fra    til    navn    
fra    til    navn    
fra    til    navn    
Sosiale forhold
26. Hvor mange familiemedlemmer (deg selv medregnet) bor i 
din husstand?
 Antall  
27. Er noen i din husstand 11 år eller yngre?
1  Ja 2  Nei
28. Hvor mange års utdanning har du medregnet folkeskole/
grunnskole?
 Angi år  
Drikkevannskilde
29. Hvilken drikkevannskilde hadde du som barn? (sett evt. flere 
kryss)
1  Egen brønn
2  Privat vannverk
3  Kommunalt vannverk
4  Vet ikke
30. Hvilken drikkevannskilde har du nå? (sett bare ett kryss)
1  Egen brønn
2  Privat vannverk
3  Kommunalt vannverk
4  Vet ikke
Toalettforhold









33.  Hvordan var den økonomiske situasjon i familien under 
oppveksten din? (sett bare ett kryss)
1  Meget god
2  God
3  Vanskelig
4  Meget vanskelig
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34. Hvordan er din økonomiske situasjon nå? (sett  bare ett kryss)
1  Meget god
2  God
3  Vanskelig
4  Meget vanskelig
“Stress”
35. Har du de siste 2 måneder følt deg ute av stand til å mes-
tre dine vanskeligheter? (sett bare ett kryss)
1  Aldri eller sjelden
2  Av og til
3  Ofte
4  Nesten Alltid
36. Har du de siste 2 måneder følt deg ”nedfor”? (sett bare ett kryss)
1  Aldri eller sjelden
2  Av og til
3  Ofte
4  Nesten Alltid
37. Føler du at du har dårlig tid også når det gjelder daglige 
gjøremål? (sett bare ett kryss)
1  Aldri eller sjelden
2  Av og til
3  Ofte
4  Nesten Alltid
Dyrehold
38. Har du/din familie hatt noen form for husdyr/kjæledyr? 
(Hvis Nei, gå til pkt. 40)
1  Ja 2  Nei
39. Hvis ja i spørsmål 38 angi da hvilket dyr og i hvilken peri-
ode i forhold til din egen alder
f.eks Husdyr     SAU   fra jeg var     5  til    8 år
 Husdyr    fra jeg var   til  år
 Husdyr    fra jeg var   til  år
 Husdyr    fra jeg var   til  år
 Husdyr    fra jeg var   til  år
 Husdyr    fra jeg var   til  år
f.eks Kjæledyr       KATT   fra jeg var     6  til    12 år
 Kjæledyr    fra jeg var   til  år
 Kjæledyr    fra jeg var   til  år
 Kjæledyr    fra jeg var   til  år
 Kjæledyr    fra jeg var   til  år
 Kjæledyr    fra jeg var   til  år
I denne delen av spørreskjemaet omtales 
Sørreisa I-undersøkelsen i 1987 flere gang-
er. Vi ber deg svare på alle spørsmålene 
uavhengig av om du deltok Sørreisa I- 
undersøkelsen i 1987 eller ikke
Mageplager
40.  Har du siden 1987 hatt smerter  eller ”verk” i magen som 
har vart i minst 2 uker? (omgangssyke (ræksjuke) regnes ikke med).
1  Ja 2  Nei
Hvis ”Ja”,   hvor ofte har du hatt disse smertene?
(sett bare ett kryss)
3  Ukentlig
4  Månedlig
5  Årlig eller sjeldnere
hvor satt smertene eller ”verken” ? (sett bare ett kryss)
6  i øvre del av magen
7  i nedre del av magen
8  i hele magen
41. Har du siden 1987 hatt sure oppstøt, halsbrann  eller 
brystbrann  nesten daglig i minst en uke?
1  Ja 2  Nei
Hvis ”Ja”,   hvor ofte har du hatt disse smertene?
(sett bare ett kryss)
3  Ukentlig
4  Månedlig
5  Årlig eller sjeldnere
42. Har du hatt diaré siste måneden
1  Ja 2  Nei
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Bruk av helsetjenester
43.  Søkte du i løpet av første året etter Sørreisa I under-
søkelsen i 1987 primærlege på grunn av sure oppstøt, 
halsbrann, brystbrann, smerter eller ”verk” i magen?
1  Ja 2  Nei
Hvis ”Ja”,  hvor ofte? (sett bare ett kryss)
 Antall legebesøk første år 
44.  Har du i løpet av det siste året søkt primærlege på grunn 
av sure oppstøt, halsbrann, brystbrann, smerter eller 
”verk” i magen?
1  Ja 2  Nei
Hvis ”Ja”,  hvor ofte? (sett bare ett kryss)
 Antall legebesøk siste år  
45.  Har du siden Sørreisa I undersøkelsen i 1987 vært henvist 
til, eller innlagt i sykehus på grunn av sure oppstøt, hals-
brann, brystbrann, smerter eller ”verk” i magen?
1  Ja 2  Nei
Hvis ”Ja”
 Hvilket sykehus?   
 Hvilket årstall?   
46.  Har du siden 1987 brukt syrenøytraliserende eller syre-
hemmende medisin, daglig eller av og til?
1  Ja 2  Nei




Har du fått ett eller flere av medisinene på resept? (sett ett 
eller flere kryss) 
7  Ja, vanlig resept
8  Ja, blå resept
9  Nei
47.  Har du siden 1987  fått påvist noen av følgende sykdom-
mer? (Sett ett eller flere kryss)
1  Magekatarr
2  Magesår
3  Sår på tolvfingertarmen
4  Betennelse i spiserøret
5  Kreft i magesekken
6  Kreft i spiserøret
7  Mellomgulvsbrokk
8  Ingen
Hvordan ble sykdommen påvist?
9  Gastroskopi
10  Annet  
Hvor ble du undersøkt?
11  RiTø/UNN
12  Kommunelegen i Sørreisa
13  Dr. Stakkevold
14  Annet sted  
48.  Har du siden 1987 fått påvist magesårsbakterien 
Helicobacter pylori?
1  Ja 2  Nei




Hvor ble du undersøkt?
11  RiTø/UNN
12  Kommunelegen i Sørreisa
13  Dr. Stakkevold
14  Annet sted  
49. Har du siden 1987 fått behandling for å fjerne mages-
årsbakterien Helicobacter pylori?  (såkalt trippelkur; tre forskjellige 
medisiner daglig i en uke eller mer)
1  Ja 2  Nei
50.  Har du noen gang vært nødt til å skifte jobb, omskolere 
deg eller forlate arbeidsmarkedet på grunn av smerter 
eller ”verk” i mangen.
1  Ja 2  Nei
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I siste del av spørreskjemaet vil vi be deg 
svare på noen spørsmål om betydningen 
av forskjellige mageplager i hverdagen. 
Spørsmålene er formulert på en slik måte, 
at de kan sammenliknes med andre spør-
reundersøkelser  fra Norge og utlandet.
51.  Har du i løpet av den siste uken hatt plager med magen? 
(Med mageplager menes all slags smerte eller knip i 
magen) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
52.  Har du i løpet av den siste uken vært plaget av halsbrann? 
(Med halsbrann menes en sviende eller brennende følelse 
av ubehag bak brystbeinet) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
53.  Har du i løpet av den siste uken vært plaget av sure opp-
støt? (med sure oppstøt menes plutselige oppstøt av surt 
mageinnhold) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
54.  Har du i løpet av den siste uken vært plaget av sug i 
magen? (med sug i magen menes her en følelse i magen 
av behov for å spise mellom måltidene) (sett bare ett  
kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
55.  Har du i løpet av den siste uken følt deg uvel? (Med å føle 
seg uvel menes ubehagsfølelse som kan gå over i kvalme 
og brekninger/oppkast) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
56.  Har du i løpet av den siste uken vært plaget av rumling i 
magen? (Med rumling menes vibrasjoner eller ”buldring” i 
magen) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
57.  Har du i løpet av den siste uken vært plaget av 
oppblåsthet? (med oppblåsthet menes utspiling, ofte for-
bundet med en følelse av luft i magen) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
58.  Har du i løpet av den siste uken vært plaget av raping? 
(med raping menes behov for ”utlufting”, ofte forbundet 
med lindring av følelse av oppblåsthet) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
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6  Meget alvorlige plager
7  Verst tenkelige plager
59.  Har du i løpet av den siste uken vært plaget av luftav-
gang? (Med luftavgang menes her behovet for å 
slippe seg, ofte forbundet med lindring av følelse av 
oppblåsthet) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
60.  Har du i løpet av den siste uken vært plaget av forstop-
pelse? (Med forstoppelse menes minsket avføringshyp-
pighet) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
61.  Har du i løpet av den siste uken vært plaget av diaré? 
(Med diaré menes økt avføringshyppighet) (sett bare ett  
kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
62.  Har du i løpet av den siste uken vært plaget av løs 
avføring? (Hvis du har hatt vekslende hard og løs 
avføring, gjelder dette spørsmålet bare i hvilken utstrek-
ning du har følt deg plaget av at avføringen har vært løs) 
(sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
63. Har du i løpet av den siste uken vært plaget av hard 
avføring? (Hvis du har hatt vekslende hard og løs 
avføring, gjelder  dette spørsmålet bare i hvilken utstre-
kning du har følt deg plaget av at avføringen har vært 
hard) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
64.  Har du i løpet av den siste uken vært plaget av tvingende 
avføringsbehov? (Med tvingende avføringsbehov menes 
raskt oppståtte behov for å gå på toalettet, ofte forbun-
det med en følelse av mangelfull kontroll) (sett bare ett  
kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
65.  Har du i løpet av den siste uken i forbindelse med 
avføring hatt en følelse av ufullstendig tømming av tar-
men? (Med ufullstendig tømming av tarmen menes at det 
trass i anstrengelser i forbindelse med avføring gjenstår 
en følelse av ufullstendig tømming) (sett bare ett  kryss)
1  Ingen plager i det hele tatt
2  Ubetydelige plager
3  Beskjedne plager
4  Ganske alvorlige plager
5  Alvorlige plager
6  Meget alvorlige plager
7  Verst tenkelige plager
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